PARTICIPATION IN CALGB

UMCC与CALGB有着长期的合作关系。UMCC工作人员 参与行政、科学、委员会和规划 CALGB内的活动。UMCC教职员工的设计、指挥和主席 研究并将患者输入多个CALGB方案。提供资金给 继续和扩大这些活动将有助于UMCC的发展 内部第一阶段(2-4年/年)研究进入第二组阶段研究。UMCC也 进行试验性研究，这些研究构成了整个集团的概念基础 学习。UMCC看到许多新的急性白血病患者，资金将 加强UMCC的参与和这些患者进入CALGB研究。 UMCC的专业实验室，包括细胞遗传学和药理学 将作为协作努力和创新数据库的资源 以备将来CALGB研究之用。UMCC及其合作机构(VA 巴尔的摩医院)和医生(利希滕菲尔德医生、利希滕菲尔德医生和 Sachs)建议每年让80至90名患者参加CALGB研究。 参与CALGB研究将允许UMCC以及合作 医生为这些疾病的患者提供了更多的治疗选择。 UMCC已完成其内部ANL研究，寻求核实来自 另一个组成员。目前的参与包括患者的进入 与白血病一起进行了一项高剂量维持的试点研究。辅助的 活动正在评估细胞药理学和敏感性 Ara-C以及使用这两种标准的白血病细胞遗传学 和甲氨蝶呤同步的高分辨率显带技术。引航员 急性白血病的研究包括临床和药代动力学II期 AZQ大剂量阿糖胞苷等药剂的研究 与其他药物和体外分化因子相结合。UMCC 5-氮胞苷和依托泊苷对慢性粒细胞白血病CALGB方案的研究 爆炸危机。所有在UMCC看到的乳腺癌患者都可以进入 CALGB研究和近10%的第四阶段研究收益来自UMCC。 目前的第四阶段研究和几项第二阶段研究已经设计完成 并担任UMCC主席。UMCC对小细胞肺癌的研究 建立了积极的三药组合，将作为基础 目前正在提议进行一项试验性研究，用于小组激活，并 很可能成为针对这一问题的新的广泛疾病方案的一部分 疾病。UMCC还将参加选定的CALGB第二阶段研究 无论是小细胞肺癌还是非小细胞肺癌。罕见的患者 软组织肉瘤等肿瘤将进入组间 通过CALGB进行的研究。这笔赠款将允许UMCC让患者进入 CALGB研究，参与CALGB委员会，开发功勋试点 协议，监测和收集数据，以产生互惠互利的UMCC 和CALGB。

The UMCC has a longstanding relationship with CALGB. UMCC staff participate in administrative, scientific, committee and planning activities within the CALGB. The UMCC faculty design, conduct and chair studies and enter patients onto multiple CALGB protocols. Funding to continue and expand these activities will allow for the evolution of UMCC in-house phase I(2-4/year) studies into group phase II studies. UMCC also conducts pilot studies which have formed the conceptual basis for groupwide studies. UMCC sees many new patients with acute leukemia and funding will enhance UMCC participation and entry of these patients onto CALGB studies. Specialized laboratories at UMCC including cytogenetics and pharmacology will serve as a resource for collaborative efforts and innovative data base for future CALGB studies. UMCC and its collaborating institutions (VA Hospital, Baltimore) and physicians, (Drs. Lichtenfeld, Lichtenfeld and Sachs) propose to enter 80 to 90 patients per year onto CALGB studies. Participation in CALGB studies will allow UMCC as well as collaborating physicians greater treatment options for patients with these diseases. UMCC has completed its in-house ANLL study seeking to verify data from another group member. Current participation includes the entry of patients with leukemia on to a pilot study of high dose maintainence. Ancillary activities are evaluating the cellular pharmacology and sensitivity of Ara-C as well as the cytogenetics of leukemia cells utilizing both standard and methotrexate sychronized high resolution banding techniques. Pilot studies in acute leukemia include clinical and pharmacokinetic phase II studies of investigational agents such as AZQ high dose Ara-C in combination with additional agents and in vitro differentiators. A UMCC study of 5-Azacytidine and etoposide led to a CALGB protocol for CML in blast crisis. All breast cancer patients seen at UMCC are entered onto CALGB studies and nearly 10% of stage IV study accrual has come from UMCC. The current stage IV study, and several phase II studies have been designed and chaired at UMCC. UMCC studies in small cell lung cancer have established an active three drug combination which will serve as the basis for a pilot study currently being proposed for group activation and is likely to serve as a portion of the new extensive disease protocol for this disease. UMCC will also participate in selected CALGB phase II studies in both small cell and non-small cell lung cancer. Patients with uncommon tumors such as soft tissue sarcomas will be entered onto the intergroup studies through CALGB. This grant will allow UMCC to enter patients onto CALGB studies, participate on CALGB committees, develop meritorious pilot protocols, monitor and collect data to produce mutual benefit to the UMCC and CALGB.